Methods of treating diabetes mellitus
First Claim
Patent Images
1. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
- orally administering an effective amount of an insulin polypeptide derivative to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
4 Assignments
0 Petitions
Accused Products
Abstract
Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may “activate” the liver, potentially restoring normal glucose homeostasis to individuals suffering from diabetes mellitus.
-
Citations
230 Claims
-
1. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide derivative to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
16. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)
-
49. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I; Insulin Polypeptide-B—
Lj—
Gk—
R—
G′
m—
R′
—
G″
n—
T
(I)
wherein;
B is a bonding moiety;
L is a linker moiety;
G, G′ and
G″
are individually selected spacer moieties;
R is a lipophilic moiety and R′
is a polyalkylene glycol moiety, or R′
is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety; and
j, k, m and n are individually 0 or 1;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula I is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. - View Dependent Claims (50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)
-
-
85. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II; Insulin polypeptide-X(CH2)mY(C2H4O)nR
(II)
wherein;
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula II is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. - View Dependent Claims (86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)
-
-
114. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III; Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula III is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. - View Dependent Claims (115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141)
-
-
142. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV;
wherein;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula IV is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. - View Dependent Claims (143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169)
-
-
170. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula V is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. - View Dependent Claims (171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187)
-
-
188. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
-
189. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it stabilizes peripheral glucose concentration to within about +/−
50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
-
190. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration. - View Dependent Claims (191)
-
192. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the patient.
-
193. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and about 1,000 U/ml within about 60 minutes of administration.
-
194. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/−
50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
-
195. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration. - View Dependent Claims (196)
-
197. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
-
198. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I; Insulin Polypeptide-B—
Lj—
Gk—
R—
G′
m—
R′
—
G″
n—
T
(I)
wherein;
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G′ and
G″
are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R′
is a polyalkylene glycol moiety, or R′
is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and
j, k, m and n are individually 0 or 1;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
-
-
199. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I; Insulin Polypeptide-B—
Lj—
Gk—
R—
G′
m—
R′
—
G″
n—
T
(I)
wherein;
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G′ and
G″
are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R′
is a polyalkylene glycol moiety, or R′
is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and
j, k, m and n are individually 0 or 1;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/−
50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
-
-
200. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I; Insulin Polypeptide-B—
Lj—
Gk—
R—
G′
m—
R′
—
G″
n—
T
(I)
wherein;
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G′ and
G″
are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R′
is a polyalkylene glycol moiety, or R′
is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and
j, k, m and n are individually 0 or 1;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration. - View Dependent Claims (201)
-
-
202. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I; Insulin Polypeptide-B—
Lj—
Gk—
R—
G′
m—
R′
—
G″
n—
T
(I)
wherein;
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G′ and
G″
are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R′
is a polyalkylene glycol moiety, or R′
is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and
j, k, m and n are individually 0 or 1;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
-
-
203. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II; Insulin polypeptide-X(CH2)mY(C2H4O)nR
(II)
wherein;
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
-
-
204. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II; Insulin polypeptide-X(CH2)mY(C2H4O)nR
(II)
wherein;
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/−
50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
-
-
205. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II; Insulin polypeptide-X(CH2)mY(C2H4O)nR
(II)
wherein;
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration. - View Dependent Claims (206)
-
-
207. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II; Insulin polypeptide-X(CH2)mY(C2H4O)nR
(II)
wherein;
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
-
-
208. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III; Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
-
-
209. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III; Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/−
50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
-
-
210. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III; Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration. - View Dependent Claims (211)
-
-
212. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III; Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
-
-
213. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV;
wherein;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
-
-
214. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV;
wherein;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/−
50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
-
-
215. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV;
wherein;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration. - View Dependent Claims (216)
-
-
217. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV;
wherein;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
-
-
218. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. - View Dependent Claims (219, 220)
-
-
221. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/−
50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration. - View Dependent Claims (222, 223)
-
-
224. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration. - View Dependent Claims (225, 226, 227)
-
-
228. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the patient. - View Dependent Claims (229, 230)
-
Specification